Condition: Advanced Solid Tumors · Sponsor: FoRx Therapeutics AG
The goal of this interventional study is to evaluate the safety and tolerability of escalating doses of FORX-48 as monotherapy in patients with select advanced solid tumors with BRCA1/2 mutations or other DDR deficiencies or high replication stress, and to determine the maximum tolerated dose (MTD) and Recommended Cohort Expansion Dose (RCED) of FORX-428 as monotherapy.
This description comes directly from the study's public registry record.
Jens Wuerthner, MD, PhD · +1 513-579-9911 · FORX-428-101@medpace.com
Always discuss trial participation with your own doctor first.
| Stanford University Medical Center | Palo Alto, California, United States | Recruiting |
| University of California, San Francisco | San Francisco, California, United States | Recruiting |
| START - Midwest | Grand Rapids, Michigan, United States | Recruiting |
| Washington University St. Louis | St Louis, Missouri, United States | Recruiting |
| Knight Cancer Institute | Portland, Oregon, United States | Recruiting |
| University of Texas - MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| START - San Antonio | San Antonio, Texas, United States | Recruiting |
| NEXT - Virginia Cancer Specialists | Fairfax, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07356453